Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial
On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related
read more
Dr. Abbey Presents Phase 1 DAVIO Clinical Trial Results to the Association for Research in Vision and Ophthalmology
Dr. Abbey presented the results from the Phase 1 DAVIO trial at ARVO 2023, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The trial was a first-in-human
read more
Dr. Abbey Contributes to Real-world Study of Faricimab for Neovascular Age-related Macular Degeneration
The TRUCKEE study is a real-world, collaborative effort to investigate the efficacy, durability, and safety of a monoclonal antibody treatment called faricimab in patients suffering from neovascular age-related macular degeneration (nAMD) in
read more Dr. Abbey Featured in Retina Times
Texas Retina Associates’ Ashkan Abbey, MD, was featured in the “5 Questions” segment of the latest issue of Retina Today. In the article, he discusses his passion for retina research, what led
read more FDA Approves First Treatment for Geographic Atrophy
On February 17, 2023, the U.S. Food and Drug Administration (FDA) approved intravitreal pegcetacoplan (brand name Syfovre), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Texas Retina
read more
Dr. Abbey Featured in New Retina Radio Podcast
Texas Retina Associates’ Ashkan M. Abbey, MD, was featured in a recently released New Retina Radio podcast for retina surgeons titled “Tips for Mastering Secondary IOLs.” Dr. Abbey discussed approaches to implanting
read more
Retina Today Publishes Dr. Abbey’s Research on a Potential Toxic Side Effect of Some “Dropless” Cataract Surgery
“Dropless” cataract surgery has become more popular over the past decade and involves an injection of antibiotics and/or steroids into the eye at the time of surgery to eliminate the need for
read more Dr. Abbey Presented at the American Academy of Ophthalmology 2022 Meeting
Over the weekend, Texas Retina Associates’ Ashkan M. Abbey, MD, taught a course titled “Secondary Intraocular Lens (IOL) Techniques for Retina Specialists” at the American Academy of Ophthalmology (AAO) 2022 meeting in Chicago,
read more Dr. Abbey Presented National Webinar on Treatment of Patients with Diabetic Macular Edema and 20/50 or Worse Vision
On Monday, September 19, 2022, Texas Retina Associates’ Ashkan M. Abbey, MD, delivered a webinar titled, “Does Treatment Selection Matter in Patients with Diabetic Macular Edema and 20/50 or Worse Vision?” Dr. Abbey discussed
read more
Texas Retina Associates First in the Country to Dose a Patient in the DAVIO 2 Clinical Trial
Texas Retina Associates is honored to have randomized the first patient in EyePoint Pharmaceuticals’ Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial of EYP-1901 for patients with wet macular
read more